Following these transactions, Gilson holds 9,582 shares of Arcellx common stock. The sales included broker-assisted transactions to cover tax obligations related to the vesting of restricted stock units. The company maintains a strong financial position with a current ratio of 4.29, indicating ample liquidity to meet short-term obligations. For deeper insights into Arcellx's financial health and additional metrics, investors can access the comprehensive Pro Research Report available on InvestingPro. The company maintains a strong financial position with a current ratio of 4.29, indicating ample liquidity to meet short-term obligations. For deeper insights into Arcellx's financial health and additional metrics, investors can access the comprehensive Pro Research Report available on InvestingPro.
Additionally, on January 8, 2025, Gilson conducted another sale of shares totaling $654,065, with prices ranging from $73.6929 to $75.5283. These transactions were part of a Rule 10b5-1 trading plan, which was originally established on December 18, 2023, and later modified on March 27, 2024. Despite recent price movements, analysts maintain price targets ranging from $104 to $134 for the stock.
Following these transactions, Gilson holds 9,582 shares of Arcellx common stock. The sales included broker-assisted transactions to cover tax obligations related to the vesting of restricted stock units.
In other recent news, Arcellx Inc. has seen a series of positive developments, with various firms maintaining their buy ratings and increasing their price targets. Stifel and TD Cowen highlighted the potential of Arcellx's candidate, anito-cel, in the Multiple Myeloma market, with Stifel reiterating its Buy rating and a $122.00 price target. BofA Securities increased its price target to $112 from the previous $100, while maintaining a Buy rating, following the announcement of interim pivotal iMMagine-1 data for anito-cel. Truist Securities echoed this sentiment, raising its price target to $136 from the previous $87, citing Arcellx's strong financial position and promising data for Anito-cel.
Piper Sandler maintained an Overweight rating and increased the price target to $115 following Arcellx's third-quarter 2024 earnings report. The firms noted the significant results from clinical studies on anito-cel for relapsed or refractory multiple myeloma, with the Phase 1 study showing a median progression-free survival of 30.2 months, and the Phase 2 iMMagine-1 study demonstrating a 95% overall response rate.
Arcellx's manufacturing capabilities for anito-cel were also praised, potentially giving it a significant advantage in the market for cancer treatments. These recent developments have been driven by Arcellx's progress and the upcoming release of full data from the iMMagine-1 study for anito-cel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.